Clinical Site - 15 — Bryant, Arkansas

Clinical Site - 15 is a clinical research site located in Bryant, Arkansas, United States 72022.

Crixeo Clinical Trials Trust Score: 9/100 (FAILING). This profile has not yet been claimed by the site owner.

Clinical Site - 15 has participated in 1 clinical trials.

Therapeutic areas: Rosacea, Papulopustular Rosacea.

Sponsors: Hovione Scientia Limited.

Is this your site?

Is this your site? Claim your profile and control the information sponsors and patients see.

Other research sites in Bryant

Browse all research sites in Arkansas · View every site in Bryant

• Dermatology Trial Associates
• SanRo Clinical Research Group
• Neurocrine Clinical Site
• Dermavant Investigative Site
• GSK Investigational Site
• SanRo Clinical Research Group LLC WCG Clinical Network
• Dermatology Trial Associates /ID# 264480
• Arcutis Clinical Site 106
• Dermatology Trial Associates /ID# 264587
• Cara Therapeutics Study Site
• Arcutis Clinical Study Site 221
• The Dermatology Clinic of Arkansas /ID# 218749

Sponsor Feasibility Report

Trust Score: 9/100. Verification status: Not yet accredited. Patient reviews: 0. Complaints: 0.

Frequently Asked Questions

What is the Trust Score for Clinical Site - 15?

Clinical Site - 15 has a Crixeo Trust Score of 9/100 (FAILING). Trust Scores reflect trial volume, sponsor diversity, patient reviews, address verification, and accreditation status.

How many clinical trials has Clinical Site - 15 conducted?

Clinical Site - 15 has 1 clinical trials on record. Their work covers Rosacea, Papulopustular Rosacea.

Is Clinical Site - 15 accredited by Crixeo Clinical Trials?

Clinical Site - 15 has not yet obtained Crixeo Accreditation. Site owners can claim their profile and apply for accreditation to improve visibility with sponsors and patients.

Can I submit a review or complaint about Clinical Site - 15?

Yes. Patients and trial participants can submit reviews and file complaints directly on this profile page. All submissions are reviewed before publication.